A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

NCT07019922 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Epileptic Encephalopathy
SCN2A Encephalopathy

Interventions

DRUG: 1mg elsunersen
PROCEDURE: sham procedure
DRUG: 0.5mg elsunersen

Sponsor

Praxis Precision Medicines